Core Viewpoint - Kunming Pharmaceutical Group Co., Ltd. has received the drug registration certificate for Carbonate Sevelamer Dry Suspension, enhancing its product pipeline in the chronic kidney disease (CKD) management sector [1][2]. Drug Basic Information - The drug is named Carbonate Sevelamer Dry Suspension with a specification of 0.8g and is classified as a prescription chemical drug (Category 3) [1]. - The drug registration number is 国药准字 H20254872, and it is produced by Kunming Beikenuoton Pharmaceutical Co., Ltd. [1]. Drug Indications - The drug is indicated for controlling hyperphosphatemia in adult patients with chronic kidney disease undergoing dialysis and those with serum phosphorus levels ≥1.78 mmol/L who are not on dialysis [2]. Market Context - Carbonate Sevelamer tablets were developed by Genzyme and approved in the U.S. in 2007, with the dry suspension form approved in the U.S. and EU in 2009 [2]. - In China, there are 10 approved manufacturers for Carbonate Sevelamer tablets, while only 3 for the dry suspension form, including the company [2]. - The domestic sales of Carbonate Sevelamer tablets are projected to be approximately 1.39 billion RMB in 2024 [2]. R&D Investment - The company has invested approximately 13.18 million RMB in the research and development of Carbonate Sevelamer Dry Suspension to date [3]. Strategic Impact - The approval of the drug registration certificate is expected to enhance the company's competitiveness in the chronic disease management market and contribute to its strategic focus on the aging health industry [3].

Investment Rating - The investment rating for Kunming Pharmaceutical Group is "Buy" (maintained) [1] Core Views - The company is optimizing its layout in the Sanqi industry, with a focus on "innovation + international expansion" to empower future growth [1] - In 2024, the company achieved a revenue of 8.401 billion yuan, with a year-on-year growth of 9.07% before restatement and a slight decline of 0.34% after restatement [5] - The acquisition of a 51% stake in China Resources Shenghuo is a key move to resolve competition issues and optimize the Sanqi business chain [5] - The company is optimistic about the development of the silver-haired health industry and has raised profit forecasts for 2025-2027 [5] Financial Summary - Revenue for 2024 is reported at 84.01 billion yuan, with a net profit of 6.48 billion yuan, reflecting a year-on-year increase of 45.74% before restatement and 19.86% after restatement [5] - The company expects net profits for 2025, 2026, and 2027 to be 7.45 billion yuan, 9.09 billion yuan, and 11.12 billion yuan respectively, with corresponding EPS of 0.98 yuan, 1.20 yuan, and 1.47 yuan [5] - The current price-to-earnings ratio (P/E) is projected to be 18.1, 14.8, and 12.1 for the years 2025, 2026, and 2027 respectively [5] Business Segments - In 2024, the revenue from oral medications was 3.693 billion yuan (up 1.18%), while injection revenue was 539 million yuan (down 49.09%) [6] - The cardiovascular segment generated 2.195 billion yuan (down 17.45%), while the gynecology segment saw revenue of 401 million yuan (up 15.67%) [6] Innovation and Internationalization - The company invested 143 million yuan in R&D in 2024, establishing an innovative pipeline covering key areas in elderly health and chronic diseases [7] - The company has made significant strides in internationalization, with its self-developed products receiving international procurement certification [7]